Who is sponsoring Lesions2?

Lesions2 is sponsored by Research Associates of New York, LLP.

What condition does Lesions2 study?

Lesions2 studies Gastroduodenal Ulcer.

What drugs are being tested in Lesions2?

Interventions: Naproxen, Aspirin, Celecoxib, Clopidogrel, Placebo.

What is the status of Lesions2?

Lesions2 is currently COMPLETED.

Last reviewed 2008-10-22 · How we verify

A Randomized, Blinded, Placebo-Controlled Study of the Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on Gastroduodenal Healing (Lesions2)

NCT00778193 Phase 4 COMPLETED

Gastroduodenal ulcers are extremely common in the community today. Though much has been written and observed concerning how ulcers form, not much has been described in the human model concerning how these ulcers heal. As numerous patients already suffer from gastrointestinal ulcers, further clarification of ulcer healing would be valuable in the treatment and management of these patients. The goal of this study is to investigate the effects of naproxen, aspirin, celecoxib, and clopidogrel on biopsy-induced gastroduodenal lesions in order to elucidate the mechanisms of ulcer healing. This single site, single-blind, randomized, placebo-controlled, one-week prospective study will examine ulcer healing through endoscopic, immunohistologic, and molecular PCR modalities.

Details

Lead sponsor	Research Associates of New York, LLP
Phase	Phase 4
Status	COMPLETED
Enrolment	125
Start date	2007-10
Completion	2008-03

Conditions

Gastroduodenal Ulcer

Interventions

Naproxen
Aspirin
Celecoxib
Clopidogrel
Placebo

Countries

United States